Myriad Genetics Inc (MYGN)

Short-term

Turnover ratios

Inventory Turnover:

- Myriad Genetics Inc's inventory turnover has improved over the years, increasing from 6.58 in 2020 to 10.74 in 2023, before slightly decreasing to 9.17 in 2024. This indicates that the company is managing its inventory more efficiently, with products being sold and restocked at a faster rate.

Receivables Turnover:

- The data shows that receivables turnover information is missing for all years, implying that we do not have details on how efficiently the company is collecting on its credit sales. It would be beneficial to have this data to assess the effectiveness of the company's credit policies and collection processes.

Payables Turnover:

- Similarly, data for payables turnover is not provided for any of the years, so the efficiency of the company's payment of its suppliers cannot be analyzed. This ratio is important as it indicates how quickly a company pays off its suppliers, which can impact relationships and future credit terms.

Working Capital Turnover:

- Myriad Genetics Inc's working capital turnover has shown a positive trend, increasing from 2.29 in 2020 to 6.26 in 2024. This suggests that the company is generating more revenue per dollar of working capital, reflecting improved efficiency in utilizing its working capital to generate sales. High working capital turnover can indicate effective management of assets and liabilities.

In conclusion, while the company demonstrates strong inventory turnover and working capital turnover, more information on receivables and payables turnover would provide a more comprehensive analysis of Myriad Genetics Inc's overall activity ratios.

---

Average number of days

Myriad Genetics Inc's activity ratios provide insights into how efficiently the company manages its inventory, collects receivables, and pays its payables.

1. Days of Inventory on Hand (DOH):
- The DOH ratio indicates how many days it takes for Myriad Genetics to convert its inventory into sales.
- From December 31, 2020 (55.51 days) to December 31, 2021 (28.26 days), the company significantly improved its inventory turnover efficiency.
- However, there was a slight increase in DOH from December 31, 2022 (36.32 days) to December 31, 2024 (39.80 days), indicating a potential slow-down in inventory turnover during those periods.

2. Days of Sales Outstanding (DSO):
- The DSO ratio measures the average number of days it takes Myriad Genetics to collect its accounts receivable.
- The provided data does not include DSO figures, which could signify that specific data relating to accounts receivable and the collection process is unavailable.

3. Number of Days of Payables:
- This ratio shows the average number of days it takes the company to pay off its suppliers.
- Similar to DSO, the data for the number of days of payables is not provided, suggesting that specific information regarding the company's payment practices to suppliers is not available.

Overall, while the DOH ratio indicates improvements in inventory turnover efficiency over the years, the lack of data for DSO and the number of days of payables limits a comprehensive assessment of Myriad Genetics Inc's overall activity management. This highlights the importance of evaluating multiple activity ratios to gain a holistic understanding of a company's operational efficiency.

---

Long-term

Myriad Genetics Inc's long-term activity ratios suggest the efficiency of the company in generating revenue from its assets over the years.

1. Fixed Asset Turnover: The information provided for fixed asset turnover is not available for the specified years (2020-2024), denoted as "—". This ratio typically measures a company's ability to generate sales from its investment in fixed assets, such as property, plant, and equipment. The lack of data makes it challenging to assess how effectively Myriad Genetics is utilizing its fixed assets to generate revenue during this period.

2. Total Asset Turnover: Myriad Genetics' total asset turnover ratio has shown an improving trend from 0.39 in 2020 to 0.82 in 2024. This ratio indicates the company's ability to generate sales in relation to its total assets. The increasing trend suggests that, overall, the company has been more efficient in utilizing its assets to generate revenue over the specified period.

In summary, while the specific data for fixed asset turnover is unavailable, the trend in the total asset turnover ratio indicates an improvement in Myriad Genetics Inc's efficiency in generating sales from its total assets from 2020 to 2024.